dBET1

CAS No. 1799711-21-9

dBET1( dBET 1 )

Catalog No. M12725 CAS No. 1799711-21-9

dBET1 is a proteolysis-targeting chimera (PROTAC) molecule that appendes a competitive antagonist of BET bromodomain (JQ1) to a phthalimide moiety to hijack the cereblon E3 ubiquitin ligase complex.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 60 In Stock
5MG 87 In Stock
10MG 160 In Stock
25MG 335 In Stock
50MG 500 In Stock
100MG 705 In Stock
500MG 1485 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    dBET1
  • Note
    Research use only, not for human use.
  • Brief Description
    dBET1 is a proteolysis-targeting chimera (PROTAC) molecule that appendes a competitive antagonist of BET bromodomain (JQ1) to a phthalimide moiety to hijack the cereblon E3 ubiquitin ligase complex.
  • Description
    dBET1 is a proteolysis-targeting chimera (PROTAC) molecule that appendes a competitive antagonist of BET bromodomain (JQ1) to a phthalimide moiety to hijack the cereblon E3 ubiquitin ligase complex; induces highly selective cereblon-dependent BET protein degradation in vitro (EC50=430 nM) and in vivo and delayed leukemia progression in mice.
  • In Vitro
    Treatment with dBET1 down regulates MYC and PIM1 transcription. Degradation of BRD4 by dBET1 is associated with a more potent apoptotic consequence in MV4;11 cell line. Significantly increased apoptosis after only 4 h of dBET1 treatment is enhanced at 8 h. dBET1 also induces a potent and superior inhibitory effect on MV4;11 cell proliferation at 24 hours (measured by ATP content, IC50= 0.14 μM, compare to IC50= 1.1 μM with JQ1).
  • In Vivo
    Administration of dBET1 attenuates tumor progression as determined by serial volumetric measurement, and decreases tumor weight assessed post-mortem. Acute pharmacodynamic degradation of BRD4 is observed four hours after a first or second daily treatment with dBET1 (50 mg/kg IP). A statistically significant destabilization of BRD4, down regulation of MYC and inhibition of proliferation is observed with dBET1 compare to vehicle control in excised tumors. Two weeks of dBET1 is well tolerated by mice without a meaningful effect on weight, white blood count, hematocrit or platelet count.
  • Synonyms
    dBET 1
  • Pathway
    PROTACs
  • Target
    PROTAC
  • Recptor
    BET
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1799711-21-9
  • Formula Weight
    785.273
  • Molecular Formula
    C38H37ClN8O7S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 50 mg/mL; Water: Insoluble; Ethanol: 5 mg/mL ( < 1 mg/ml refers to the product slightly soluble or insoluble )
  • SMILES
    CC(N(C1C2=NN=C(C)N2C3=C(C(C)=C(C)S3)C(C4=CC=C(Cl)C=C4)=N1)CCCCNC(COC5=CC=CC(C(N6C(CC7)C(NC7=O)=O)=O)=C5C6=O)=O)=O
  • Chemical Name
    (6S)-4-(4-chlorophenyl)-N-[4-[[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]acetyl]amino]butyl]-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Winter GE, et al. Science. 2015 Jun 19;348(6241):1376-81.
molnova catalog
related products
  • TCO-NHS ester

    TCO-NHS ester is a alkyl/ether-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules.

  • Azido-PEG1-azide

    Azido-PEG1-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

  • SNIPER(ER)-110

    SNIPER(ER)-110 is a nongenetic IAP-dependent protein eraser (SNIPER) targeting estrogen receptor α (ERα), induces ERα degradation and induces apoptosis in MCF-7 human breast cancer cells.